FDA's Latest: More Paperwork to Track Your Sandwich Ingredients
Published Date: 2/20/2026
Notice
Summary
The FDA just dropped a draft guide to help food makers, packers, and holders understand new rules about keeping extra records for certain foods. If you’re in the food biz, these rules mean more tracking paperwork to keep food safe and traceable. You’ve got until May 21, 2026, to send in your thoughts before the guide goes final—so get ready to update your record-keeping game!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Faster removal of unsafe food reduces illnesses
You should see fewer foodborne illnesses and deaths because the rule lets FDA identify and remove potentially contaminated food faster. The Food Traceability Rule enables faster identification and rapid removal of unsafe foods from the market.
Food businesses must keep extra records
If you manufacture, process, pack, or hold foods on the Food Traceability List (FTL), you must maintain records containing key data elements tied to specific critical tracking events and keep a written traceability plan. The rule applies to both domestic and foreign firms producing food for U.S. consumption and covers recordkeeping across the entire food supply chain.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20503, Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction
The FDA fixed a previous announcement about Oxandrin tablets (2.5 mg and 10 mg) being pulled from the market due to safety or effectiveness concerns. This update confirms that not only the original drug but also several generic versions were withdrawn and removed from the official drug list. Patients, doctors, and drug makers should note these changes, which affect availability and prescribing options immediately.
Previous / Next Documents
Previous: 2026-03362, Requirements for Additional Traceability Records for Certain Foods; Exemption for Cottage Cheese Regulated by the National Conference on Interstate Milk Shipments Grade “A” Pasteurized Milk Ordinance
Starting February 20, 2026, certain cottage cheese made under the Grade “A” Pasteurized Milk rules won’t have to follow extra food tracking record rules. This change helps cottage cheese makers by easing paperwork without risking safety. If you make, process, or sell these cottage cheeses, this means less hassle and no new costs.
Next: 2026-03365, State of Wyoming: NRC Staff Assessment of a Proposed Amendment to the Agreement Between the Nuclear Regulatory Commission and the State of Wyoming
The Nuclear Regulatory Commission (NRC) is proposing changes to its agreement with Wyoming about how the state handles certain nuclear materials. Wyoming’s program and staff are being reviewed to make sure they keep people safe. The public can share their thoughts by March 2, 2026, before any final decisions are made.